View Article

Abstract

The most common cause of dementia in the elderly is Alzheimer's disease. The development of treatments for Alzheimer's disease has been helped by research, at least in part. These achievements and setbacks have sparked discussion over possible gaps in our knowledge of the pathophysiology of Alzheimer's disease as well as possible hazards in the identification of therapeutic targets, development of drug candidates, diagnostics, and clinical trial design. Although there is a lot of clinical and experimental research being conducted, we must accept the likelihood that there won't be a single cure for Alzheimer's disease and that the strategy for developing new drugs to treat this condition needs to be reevaluated. Preclinical research is continuously shedding light on various aspects of the intricate jigsaw that is Alzheimer's disease, and a review of this data may point to patterns of pharmacological interactions rather than specific possible therapeutic targets. We may be getting closer to creating the best possible pharmaceutical strategy for treating Alzheimer's disease thanks to the several encouraging randomized controlled studies that are currently underway and the growing cooperation between pharmaceutical corporations, basic scientists, and clinical researchers. First Off Alzheimer's disease primarily affects the elderly, and as the world's population ages, the illness is becoming more widespread and burdensome on society, the economy, and human resources. There is an urgent need for effective treatments. Although it is still up for debate, current Alzheimer's disease medications improve symptoms by targeting cholinergic and glutamatergic neurotransmission. 1 (table).2- 15 Many substances are in various stages of development, to find medicines that affect disease. We present an up-to-date and thorough overview of the state of medication development for Alzheimer's disease in this review, highlighting therapeutic methods that are still in the preclinical stages and concentrating mostly on substances that are being tested on humans. The main mechanisms of action of drugs are discussed, including those that impact neurotransmission, those that stop misfolded proteins (tau and amyloid ? *A?+) from building up, and those that repair mitochondrial function or the growth factor balance, among other therapeutic modalities. For pragmatic reasons, this subject has historically been divided into specialized discussions of various treatment approaches. We summarize all of the clinical data that are currently available in this paper, discussing them from both a clinical and design standpoint. We also go over general issues related to this subject, such as the underlying dominant hypothesis (one protein, one drug, one disease), its implications, and the necessity of changing it. This theory states that the goal of medication research is to identify a specific substance that affects a single, targeted illness to achieve the intended therapeutic outcomes. A strategy like this, meanwhile, might not be appropriate given how complicated Alzheimer's disease is. cholinergic medications Acetylcholinesterase inhibitors can help restore the reduced cholinergic transmission caused by the early loss of basal forebrain cholinergic neurons, which is a hallmark of the neuropathology of Alzheimer's disease.[1]

Keywords

risk factors, neurodegeneration, Alzheimer's disease, management, diagnosis, and therapy

Reference

  1. M. Citron, Alzheimer's disease: strategies for disease modification, Nat. Rev. Drug Discov. 2010; (9): 387–398.
  2. Indu Bhushan*; Manjot Kour; Guneet Kour; Shriya Gupta; Supriya Sharma; Arvind Yadav Department of Biotechnology, Shri Mata Vaishno Devi University, Katra, India
  3. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY
  4. Wen Y, Yang SH, Liu R, Perez EJ, Brun-Zinkernagel AM, Koulen P, et al. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochimica et biophysica acta. 2007 Apr; 1772(4):473–83. [PubMed: 17113760]
  5. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. Jama. 1999 Feb 3; 281(5):438–45. [PubMed: 9952204]
  6. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010 Dec; 68(Suppl 2):S74–87. [PubMed: 21091952]
  7. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer's amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004 Nov; 35(11 Suppl 1):2628–31. [PubMed: 15459432]
  8. Dickson, D.W., Crystal, H.A. & Bevona, C. ‘Correlations of synaptic and pathological markers with cognition of the elderly’, Neurobiology & Aging. 1995; 16: 285
  9. Hu X, Crick SL, Bu G, Freiden C, Pappu RV, Lee JM ‘Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide’, Proceedings of the National Academy of Sciences of the United States. 2010; 106(48): 20324-20329.
  10. Reisberg, B. 'An Overview of Current Concepts of Alzheimer's Disease, Senile Dementia, and Age-Associated Cognitive Decline', in Reisberg, B. (ed), Alzheimer's Disease, the Standard Reference, The Free Press: New York. 1983;
  11. Goldblum, M-C., Gomez, C-M. &Dalla Barba, G. ‘The influence of semantic and perceptual encoding on recognition memory in Alzheimer’s disease’, Neuropsychologia. 1998; 36(8): 717-729.
  12. Thompson, S.B.N. ‘Dementia: A Guide for Health Care Professionals’. Aldershot: Arena.
  13. . McDowell, I. ‘Alzheimer’s disease: Insights from epidemiology’, Aging (Milano). 2001; 13( 3): 143-162
  14. Blennow K, de Leon MJ, and Zetterberg H. Alzheimer’s disease. Lancet. 2006; 29: 387-403.
  15. Yiannopoulou KG and Papageorgiou SG. Current and future treatments for Alzheimer’s disease. There Adv Neurol Disord. 2013; 6: 19-33.
  16. Lukiw WJ. Amyloid beta (Aß) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD). Expert OpinEmerg Drugs. 2012
  17. Guerreiro, R.; Bras, J. The age factor in Alzheimer’s disease. Genome Med. 2015, 7, 106. [CrossRef] [PubMed]
  18.  Riedeldel, B.C.; Thompson, P.M.; Brinton, R.D. Age, APOE and sex: Triad of risk of Alzheimer’s disease. J. Steroid Biochem. Mol. Biol. 2016, 160, 134–147. [CrossRef] [PubMed]
  19. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019, 15, 565–581. [CrossRef] [PubMed]
  20.   Bekris, L.M.; Yu, C.E.; Bird, T.D.; Tsuang, D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010, 23, 213–227. [CrossRef] [PubMed]
  21. Van Cauwenberghe, C.; Van Broeckhoven, C.; Sleegers, K. The genetic landscape of Alzheimer's disease: Clinical implications and perspectives. Genet. Med. Off. J. Am. Coll. Med Genet. 2016, 18, 421–430. [CrossRef]
  22. Khanahmadi, M.; Farhud, D.D.; Malmir, M. Genetic of Alzheimer’s disease: A narrative review article. Iran. J. Public Health 2015, 44, 892–901.
  23. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharmacal Res. 2013, 36, 375–399. [CrossRef]
  24. Babic, T. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 67, 558. [CrossRef] [PubMed]
  25. Ferreira-Vieira, T.H.; Guimaraes, I.M.; Silva, F.R.; Ribeiro, F.M. Alzheimer’s disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 2016, 14, 101–115. [CrossRef
  26. Monczor, M. Diagnosis and treatment of Alzheimer’s disease. Curr. Med. Chem. Cent. Nerv. Syst. Agents 2005, 5, 5–13. [CrossRef]
  27. Hampel, H.; Mesulam, M.M.; Cuello, A.C.; Farlow, M.R.; Giacobini, E.; Grossberg, G.T.; Khachaturian, A.S.; Vergallo, A.; Cavedo, E.; Snyder, P.J.; et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain A J. Neurol. 2018, 141, 1917–1933. [CrossRef]
  28. Paroni, G.; Bisceglia, P.; Seripa, D. Understanding the amyloid hypothesis in Alzheimer’s disease. J. Alzheimer’s Dis. Jad 2019, 68, 493–510. [CrossRef] [PubMed
  29. Kametani, F.; Hasegawa, M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front. Neurosci. 2018, 12, 25. [CrossRef]
  30. Ricciarelli, R.; Fedele, E. The amyloid cascade hypothesis in Alzheimer’s disease: It’s time to change our mind. Curr. Neuropharmacol. 2017, 15, 926–935. [CrossRef]
  31. Guerreiro, R.; Bras, J. The age factor in Alzheimer’s disease. Genome Med. 2015, 7, 106. [CrossRef] [PubMed
  32. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019, 15, 565–581. [CrossRef] [PubMed]
  33. Bekris, L.M.; Yu, C.E.; Bird, T.D.; Tsuang, D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010, 23, 213–227. [CrossRef] [PubMed]
  34. Van Cauwenberghe, C.; Van Broeckhoven, C.; Sleegers, K. The genetic landscape of Alzheimer's disease: Clinical implications and perspectives. Genet. Med. Off. J. Am. Coll. Med Genet. 2016, 18, 421–430. [CrossRef].

Photo
Poonam Manikrao Dapke
Corresponding author

Department Of Pharmacy, LBYP Collage Of Pharmacy Pathri, India

Photo
Ms.Sonali kalam
Co-author

Department Of Pharmacy, LBYP Collage Of Pharmacy Pathri, India

Photo
Dr. Gajanan Sanap
Co-author

Department Of Pharmacy, LBYP Collage Of Pharmacy Pathri, India

Poonam Dapke* Ms. Sonali Kalam, Dr. Gajanan Sanap, Alzheimer's Disease: A Review, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 11, 282-292. https://doi.org/10.5281/zenodo.10130203

More related articles
Systematization Of Environmental Risk Factors For ...
Bhagyashri Randhawan, Nagare A.G, Avhad V.R, Hawaldar R.H, Jathar...
Effective Communication In Pharmacovigilance...
Prajakta Pujari , Sonali Magdum, Kajal Shinde, Darshani Taral, Pr...
Antimicrobial Activity Of Morus Alba Leaf Extract ...
Indranil Chatterjee, Bishan Sarkar, Pritam Ghosh, Suchetan Sarkar...
Related Articles
Custard Apple Leaves Hypoglycemic Jellies ...
Vaishnavi V. Gampawar, Shubham B. Dongare , Satish P. Mohitkar , Mahesh A. Hadke, ...
Review Of Monkeypox Virus :Symptoms ,Pathogenesis ,Diagnosis And Treatment...
Pratiksha A. Udawant, Sabafarin Shaikh, Khare Komal, Mayur S. Bhosle, Sushmita Chavan, ...
Formulation And Evaluation Of Paracetamol Tablet To Assess ...
Somnath Wadghane , Rajesh Mokate, Jayshree Kokat, Puja Aher, ...
Systematization Of Environmental Risk Factors For Malignancy...
Bhagyashri Randhawan, Nagare A.G, Avhad V.R, Hawaldar R.H, Jathar N.B, Narwade S.N, ...
More related articles
Systematization Of Environmental Risk Factors For Malignancy...
Bhagyashri Randhawan, Nagare A.G, Avhad V.R, Hawaldar R.H, Jathar N.B, Narwade S.N, ...
Effective Communication In Pharmacovigilance...
Prajakta Pujari , Sonali Magdum, Kajal Shinde, Darshani Taral, Prajakta Chaugule, Sadhana Pujari, Ra...
Antimicrobial Activity Of Morus Alba Leaf Extract Against Potent Oral Pathogens ...
Indranil Chatterjee, Bishan Sarkar, Pritam Ghosh, Suchetan Sarkar, ...
Systematization Of Environmental Risk Factors For Malignancy...
Bhagyashri Randhawan, Nagare A.G, Avhad V.R, Hawaldar R.H, Jathar N.B, Narwade S.N, ...
Effective Communication In Pharmacovigilance...
Prajakta Pujari , Sonali Magdum, Kajal Shinde, Darshani Taral, Prajakta Chaugule, Sadhana Pujari, Ra...
Antimicrobial Activity Of Morus Alba Leaf Extract Against Potent Oral Pathogens ...
Indranil Chatterjee, Bishan Sarkar, Pritam Ghosh, Suchetan Sarkar, ...